July 13, 2018
The Alzheimer's Drug Discovery Foundation (ADDF) announces seven new investments, including clinical trials, novel drug programs, and a prevention program, which reflects the comprehensive nature of the ADDF's funding strategy.
May 1, 2018
The ADDF has joined an initiative from the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium that will improve diagnosis and the development of targeted therapies for Alzheimer's disease.
January 8, 2018
The ADDF announces nearly $1.8 million in new funding, which reflects our commitment to advancing drugs in or near human clinical trials.
November 14, 2017
The Alzheimer’s Drug Discovery Foundation (ADDF) announces three new investments, all of which are for programs that the ADDF previously funded.
October 24, 2017
Learn why combination therapy holds such promise for treating Alzheimer's disease, and why Amylyx's drug is the first such therapy we are funding.
October 24, 2017
We are jointly funding a new combination therapy clinical trial for Alzheimer’s disease to be conducted by Amylyx Pharmaceuticals.
September 13, 2017
Nearly 200 academic and industry researchers came together to share updates on innovative preclinical and clinical-stage Alzheimer’s disease research at the 18th Annual Conference on Alzheimer's Drug Discovery.
September 5, 2017
At our 18th Annual Conference on Alzheimer’s Drug Discovery in Jersey City, the impact of our approach will take center stage.
August 17, 2017
A growing body of evidence suggests that inflammation in the brain is implicated in the development of Alzheimer's.
March 7, 2017
We recently awarded eight new grants totaling over $4 million to advance treatments for Alzheimer’s and related dementias. Several of the awards support new approaches to treating these diseases.